Tarsus Pharmaceuticals Inc (TARS) Stock Analysis

Tarsus Pharmaceuticals Inc (TARS) is a publicly traded company in the HEALTHCARE sector. It trades at $57.41, carries a market capitalization of $2.54B. This page summarizes the public market data, fundamentals, and frequently asked questions for TARS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Tarsus Pharmaceuticals Inc currently has a Bullish sentiment score of 0.18.

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, dedicated to advancing innovative therapeutic candidates specifically targeting ophthalmic diseases. With a pipeline centered around groundbreaking treatments for conditions such as dry eye disease and other vision-related disorders, Tarsus aims to fill significant unmet medical needs in the ophthalmic market. The company's commitment to robust clinical development supports its mission to e...

GNG Research Analysis

GNG Research scores Tarsus Pharmaceuticals Inc (TARS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TARS.

Frequently Asked Questions

Does TARS pay dividends?

Tarsus Pharmaceuticals Inc (TARS) does not currently pay a regular dividend.

What is TARS's market cap?

Tarsus Pharmaceuticals Inc (TARS) has a market capitalization of $2.54B with a current stock price of $57.41.